Read April's eNews
Growing Opportunities for our Network, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Review of this year's BLSA (Building Life Science Adventures)
✅ Tony Jones reviews our Inaugural Annual Awards
✅ Boston Bootcamp Winners and What they Can Look Forward To
Regulatory Compliant Tissue Microarrays
AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.
These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
As technologies emerge that enable a wide range of naturally occurring medicinal compounds to be reproduced by a host plant within a controlled environment, is it time to review the use of plants as biofactories? Innovation facilitators Agri-TechE are partnering with the life-sciences network OneNucleus to explore the market potential of using plant factories to mass produce rare drugs. Find out more about the event here.
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
• Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS
• The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development
Norwich Research Park showcased its latest collaborations with industry at its Enterprise Tuesday event held on Tuesday 5 March at the John Innes Conference Centre.
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its second Innovation & Entrepreneurship Awards.
Produced using a patented dry-spinning technology - CollaFibR™ from AMSBIO is a highly consistent collagen fibre matrix that closely mimics the biomechanical and biochemical properties of natural collagen scaffolds, offering a highly accurate representation of in-vivo conditions.
These innovative collagen fibres are seamlessly produced on a commercial scale using an automated state-of-the-art Good Manufacturing Process, catering to a variety of applications in 3D cell culture and tissue engineering.
FemTech and Women’s Health start-ups urged to join Discovery Park’s growth programme, offering a support package worth over £50K
The Special Edition of the ‘Discovery Spark’ growth programme was announced at Kent & Medway Women’s Health Innovation Summit